Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 612

1.

Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.

Radfar S, Wang Y, Khong HT.

J Immunol. 2009 Nov 15;183(10):6800-7. doi: 10.4049/jimmunol.0901747. Epub 2009 Oct 21.

2.

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.

Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53.

3.

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.

Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abdulsamad K, Adams SL.

Immunol Invest. 2008;37(4):315-38. doi: 10.1080/08820130802083762.

PMID:
18569073
4.

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.

Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abulsamad K, Adams SL.

Clin Immunol. 2008 Aug;128(2):205-18. doi: 10.1016/j.clim.2008.03.518. Epub 2008 Jun 3.

PMID:
18511346
5.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
6.

Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.

Homma S, Sagawa Y, Komita H, Koido S, Nagasaki E, Ryoma Y, Okamoto M.

Cancer Immunol Immunother. 2007 Aug;56(8):1265-74. Epub 2007 Jan 12.

PMID:
17219148
7.

Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.

Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2224-31.

9.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
10.

Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.

Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang GF, Osada S, Balazs M, Adany R, Kawaguchi Y, Yoshida K, Takami T.

J Leukoc Biol. 2008 Sep;84(3):679-88. doi: 10.1189/jlb.1107729. Epub 2008 Jun 19.

11.

CD4+ T cells tumor specific response exists in L615 leukemia mice: adoptive transfer in combination with cyclophosphamide.

Zhang S, Zhang HJ, Wang HY, Wang Q, Li WF, Yu L.

Exp Oncol. 2004 Jun;26(2):156-7.

PMID:
15273668
12.

Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism.

Cheng WF, Chang MC, Sun WZ, Lee CN, Lin HW, Su YN, Hsieh CY, Chen CA.

Gene Ther. 2008 Jul;15(13):1007-16. doi: 10.1038/gt.2008.25. Epub 2008 Mar 20.

PMID:
18356819
13.

Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.

Jorritsma A, Bins AD, Schumacher TN, Haanen JB.

Cancer Res. 2008 Apr 1;68(7):2455-62. doi: 10.1158/0008-5472.CAN-07-5254.

14.

Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?

Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW.

Med Hypotheses. 2008 Nov;71(5):802-4. doi: 10.1016/j.mehy.2008.06.022. Epub 2008 Aug 8.

PMID:
18691831
16.

Cytokine-based therapy and biochemotherapy for advanced melanoma.

Atkins MB.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2353s-2358s. Review.

17.

EGF-IL-18 fusion protein as a potential anti-tumor reagent by induction of immune response and apoptosis in cancer cells.

Lu J, Peng Y, Zheng ZJ, Pan JH, Zhang Y, Bai Y.

Cancer Lett. 2008 Feb 18;260(1-2):187-97. Epub 2007 Dec 21.

PMID:
18160214
18.

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.

Yoon SH, Lee JM, Cho HI, Kim EK, Kim HS, Park MY, Kim TG.

Cancer Gene Ther. 2009 Jun;16(6):489-97. doi: 10.1038/cgt.2008.98. Epub 2008 Dec 19.

PMID:
19096447
19.

Large-scale production and characterization of novel CD4+ cytotoxic T cells with broad tumor specificity for immunotherapy.

Jursik C, Prchal M, Grillari-Voglauer R, Drbal K, Fuertbauer E, Jungfer H, Albert WH, Steinhuber E, Hemetsberger T, Grillari J, Stockinger H, Katinger H.

Mol Cancer Res. 2009 Mar;7(3):339-53. doi: 10.1158/1541-7786.MCR-07-2208. Epub 2009 Feb 24.

20.

A simple and effective method for cancer immunotherapy by inactivated allogeneic leukocytes infusion.

Su X, Guo S, Zhou C, Wang D, Ma W, Zhang S.

Int J Cancer. 2009 Mar 1;124(5):1142-51. doi: 10.1002/ijc.24045.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk